drugset / Trial / NCT03692663
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Phase 0
Unknown
9 enrolled
Allife Medical Science and Technology Co., Ltd.
Tianjin People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2023-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TABP EIC | Unknown | 0.5 cells | Intravenous |
| Subject | TABP EIC | Unknown | 10 cells | Intravenous |
| Subject | TABP EIC | Unknown | 30 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |